Predicted protein targets (top 10)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | NPSR1 | Q6W5P4 | 1/20 | 0.52 |
| ▸ | RAB9A | P51151 | 1/20 | 0.51 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.50 |
| ▸ | MEN1 | O00255 | 1/20 | 0.50 |
| ▸ | POLB | P06746 | 1/20 | 0.50 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.50 |
| ▸ | POLR1A | O95602 | 2/20 | 0.49 |
| ▸ | APP | P05067 | 1/20 | 0.49 |
| ▸ | DRD2 | P14416 | 1/20 | 0.49 |
| ▸ | DRD4 | P21917 | 1/20 | 0.49 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL21883951 | 0.99 | MEN1 (0.52) | NPSR1RAB9AALDH1A1MEN1POLB | |
| SCHEMBL21883927 | 0.88 | KDM4E (0.55) | ALDH1A1MEN1POLBKMT2ADRD2 | |
| SCHEMBL24062684 | 0.88 | KMT2A (0.62) | ALDH1A1MEN1KMT2A | |
| SCHEMBL24506197 | 0.88 | NPSR1 (0.49) | NPSR1RAB9AALDH1A1MEN1POLB | |
| SCHEMBL2740260 | 0.85 | MEN1 (0.53) | NPSR1RAB9AALDH1A1MEN1POLB | |
| SCHEMBL24333908 | 0.85 | NPSR1 (0.56) | NPSR1ALDH1A1MEN1POLBKMT2A | |
| SCHEMBL19132941 | 0.84 | ALDH1A1 (0.52) | ALDH1A1MEN1POLBKMT2ADRD2 | |
| SCHEMBL21347710 | 0.83 | POLB (0.55) | NPSR1ALDH1A1MEN1POLBKMT2A | |
| SCHEMBL12333392 | 0.83 | POLB (0.62) | NPSR1ALDH1A1MEN1POLBKMT2A | |
| SCHEMBL11484492 | 0.83 | MEN1 (0.57) | NPSR1RAB9AALDH1A1MEN1POLB |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 7 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20230381323-A1 | RELEASABLE CONJUGATES | FISH & RICHARDSON PC | 2023-11-30 | — | — | US | disclosed |
| US-11786599-B2 | Releasable conjugates | QUIAPEG PHARMACEUTICALS AB (SE) | 2023-10-17 | — | — | US | disclosed |
| EP-4011396-A1 | RELEASABLE CONJUGATES | QuiaPEG Pharmaceuticals AB (SE) | 2022-06-15 | — | — | EP | disclosed |
| US-11357828-B2 | Releasable GLP-1 conjugates | QUIAPEG PHARMACEUTICALS AB (SE) | 2022-06-14 | — | — | US | disclosed |
| US-20220118055-A1 | RELEASABLE GLP-1 CONJUGATES | FISH & RICHARDSON PC | 2022-04-21 | — | — | US | disclosed |
| EP-3592393-B1 | RELEASABLE CONJUGATES | QUIAPEG PHARMACEUTICALS AB (SE) | 2021-12-01 | — | — | EP | disclosed |
| WO-2020053815-A1 | RELEASABLE GLP-1 CONJUGATES | QUIAPEG PHARMACEUTICALS AB (SE) | 2020-03-19 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (4 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20230381323-A1 | RELEASABLE CONJUGATES | GUSB, ABCB11, UGT2B7 | NPSR1 430/4885RAB9A 146/4885ALDH1A1 72/4885 |
| US-11357828-B2 | Releasable GLP-1 conjugates | GLP1R, GIPR, IAPP | NPSR1 154/4885RAB9A 165/4885ALDH1A1 681/4885 |
| US-11786599-B2 | Releasable conjugates | GUSB, ABCB11, UGT2B7 | NPSR1 430/4885RAB9A 146/4885ALDH1A1 72/4885 |
| US-20220118055-A1 | RELEASABLE GLP-1 CONJUGATES | GLP1R, GIPR, IAPP | NPSR1 154/4885RAB9A 165/4885ALDH1A1 681/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.